Until finding out more clinically relevant imaging modalities and appropriate patient selection criteria, this information can be useful in the evaluation of tumor response to NCT and in the planning of surgery for breast cancer patients of all subtypes except for HER2-positive tumors after NCT. Here, ERBB2 is linked to breast cancer.